Tumor vaccines and beyond
- PMID: 21067312
- PMCID: PMC8751546
- DOI: 10.3109/14653249.2010.530649
Tumor vaccines and beyond
Abstract
For the last two decades the immunotherapy of patients with solid and hematopoietic tumors has met with variable success. We have reviewed the field of tumor vaccines to examine what has worked and what has not, why this has been the case, how the anti-tumor responses were examined, and how we can make tumor immunity successful for the majority of individuals rather than for the exceptional patients who currently show successful immune responses against their tumors.
Conflict of interest statement
Similar articles
-
Minor histocompatibility antigens: allo target molecules for tumor-specific immunotherapy.Cancer J. 2004 Jan-Feb;10(1):1-7. doi: 10.1097/00130404-200401000-00001. Cancer J. 2004. PMID: 15000488 Review.
-
Personalized neoantigen vaccination with synthetic long peptides: recent advances and future perspectives.Theranostics. 2020 May 15;10(13):6011-6023. doi: 10.7150/thno.38742. eCollection 2020. Theranostics. 2020. PMID: 32483434 Free PMC article. Review.
-
Specificity in cancer immunotherapy.Semin Immunol. 2008 Oct;20(5):276-85. doi: 10.1016/j.smim.2008.07.001. Epub 2008 Aug 5. Semin Immunol. 2008. PMID: 18684640 Free PMC article. Review.
-
NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives.Front Immunol. 2018 May 1;9:947. doi: 10.3389/fimmu.2018.00947. eCollection 2018. Front Immunol. 2018. PMID: 29770138 Free PMC article. Review.
-
The identification of cancer antigens: impact on the development of cancer vaccines.Cancer J. 2000 Apr;6 Suppl 2:S142-9. Cancer J. 2000. PMID: 10803829 Review. No abstract available.
Cited by
-
Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response.Signal Transduct Target Ther. 2022 Sep 19;7(1):331. doi: 10.1038/s41392-022-01136-2. Signal Transduct Target Ther. 2022. PMID: 36123348 Free PMC article. Review.
-
Clinically feasible approaches to potentiating cancer cell-based immunotherapies.Hum Vaccin Immunother. 2015;11(4):851-69. doi: 10.1080/21645515.2015.1009814. Hum Vaccin Immunother. 2015. PMID: 25933181 Free PMC article. Review.
-
Examining T cells at vaccine sites of tumor-bearing hosts provides insights to dysfunctional T-cell immunity.J Immunother. 2013 Jan;36(1):41-51. doi: 10.1097/CJI.0b013e318274590e. J Immunother. 2013. PMID: 23211619 Free PMC article.
-
Current Development of Therapeutic Vaccines in Lung Cancer.Vaccines (Basel). 2025 Feb 14;13(2):185. doi: 10.3390/vaccines13020185. Vaccines (Basel). 2025. PMID: 40006732 Free PMC article. Review.
-
Expression of the brother of the regulator of imprinted sites gene in the sputum of patients with lung cancer.Korean J Thorac Cardiovasc Surg. 2014 Aug;47(4):378-83. doi: 10.5090/kjtcs.2014.47.4.378. Epub 2014 Aug 5. Korean J Thorac Cardiovasc Surg. 2014. PMID: 25207247 Free PMC article.
References
-
- Fialkow P, Singer J, Adamson J, Vaidya K, Dow L, Ochs J, et al. Acute nonlymphocytic leukemia: heterogeneity of stem cell origin. Blood 1981;57:1068–73. - PubMed
-
- Fialkow PJ, Singer JW, Raskind WH, Adamson JW, Jacobson RJ, Bernstein ID, et al. Clonal development, stem-cell differentiation, and clinical remissions in acute nonlymphocytic leukemia. N Engl J Med 1987;317:468–73. - PubMed
-
- Fearon ER, Hamilton SR, Vogelstein B. Clonal analysis of human colorectal tumors. Science 1987;238:193–7. - PubMed
-
- Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988;319:525–32. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous